dc.contributor.author | Sahin, Burc E. | |
dc.contributor.author | Çelikbilek, Asuman | |
dc.contributor.author | Koçak, Yusuf | |
dc.contributor.author | İlanbey, Bilal | |
dc.contributor.author | Saltoğlu, Gamze T. | |
dc.contributor.author | Konar, Naime M. | |
dc.contributor.author | Hızmalı, Lokman | |
dc.date.accessioned | 2023-03-14T12:55:58Z | |
dc.date.available | 2023-03-14T12:55:58Z | |
dc.date.issued | 2023 | en_US |
dc.identifier.citation | Sahin, B. E., Celikbilek, A., Kocak, Y., Ilanbey, B., Saltoglu, G. T., Konar, N. M., & Hizmali, L. (2023). Neurological symptoms and neuronal damage markers in acute COVID‐19: Is there a correlation? A pilot study. Journal of Medical Virology, 95(1), e28240. | en_US |
dc.identifier.issn | 0146-6615 | |
dc.identifier.uri | https://doi.org/10.1002/jmv.28240 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12513/4967 | |
dc.description.abstract | A wide spectrum of neurological symptoms (NS) has been described in patients with COVID-19. We examined the plasma levels of neuron-specific enolase (NSE) and neurofilament light chain (NFL) together, as neuronal damage markers, and their relationships with clinical severity in patients with NS at acute COVID-19. A total of 20 healthy controls and 59 patients with confirmed COVID-19 were enrolled in this pilot prospective study. Serum NSE and NFL levels were measured by using the enzyme-linked immunoassay method from serum samples. Serum NSE levels were found to be significantly higher in the severe group than in the nonsevere group (p = 0.034). However, serum NFL levels were similar between the control and disease groups (p > 0.05). For the mild group, serum NFL levels were significantly higher in patients with the sampling time >= 5 days than in those with the sampling time <5 days (p = 0.019). However, no significant results for NSE and NFL were obtained in patients with either single or multiple NS across the groups (p > 0.05). Increased serum NSE levels were associated with disease severity regardless of accompanied NS in patients with acute COVID-19 infection. However, serum NFL levels may have a role at the subacute phase of COVID-19. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Wiley | en_US |
dc.relation.isversionof | 10.1002/jmv.28240 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | neurofilament light chain | en_US |
dc.subject | neurological symptoms | en_US |
dc.subject | neuron-specific enolase | en_US |
dc.subject | neuronal damage | en_US |
dc.title | Neurological symptoms and neuronal damage markers in acute COVID-19: Is there a correlation? A pilot study | en_US |
dc.type | article | en_US |
dc.relation.journal | Journal Of Medıcal Vırology | en_US |
dc.contributor.department | Tıp Fakültesi | en_US |
dc.contributor.authorID | Burç Esra Şahin/ 0000-0003-1008-2743 | en_US |
dc.contributor.authorID | Asuman Çelikbilek / 0000-0002-2367-1128 | en_US |
dc.contributor.authorID | Yusuf Koçak / 0000-0003-4511-1321 | en_US |
dc.contributor.authorID | Bilal İlanbey / 0000-0002-7614-281X | en_US |
dc.contributor.authorID | Naime Meriç Konar / 0000-0002-6593-7617 | en_US |
dc.contributor.authorID | Lokman Hızmalı / 0000-0001-9548-3030 | en_US |
dc.identifier.volume | 95 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.startpage | 1 | en_US |
dc.identifier.endpage | 7 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |